Pharmaceutical News

RSS

Study elaborates relationship between obesity and MDD-R, long-term use of ADs

This study demonstrates that patients using antidepressants continuously, mostly serotonin-selective reuptake inhibitors, show significantly more overweight and obesity than those using them intermittently or not at all.

18 Jan 2011

FDA approves Natroba for treatment of head lice infestations

The U.S. Food and Drug Administration today approved Natroba (spinosad) Topical Suspension 0.9% for the treatment of head lice infestation in patients ages 4 years and older.

18 Jan 2011

FDA approves ParaPRO's Natroba for topical treatment of head lice

ParaPRO, LLC announced today that the U.S. Food and Drug Administration has approved Natroba Topical Suspension, 0.9% to eliminate head lice. Natroba received approval as a prescription medication and is indicated for the topical treatment of head lice infestations in patients four years of age and older.

18 Jan 2011

Z-Medica develops new version of QuikClot Combat Gauze

Z-Medica Corporation, a medical device company developing innovative hemostatic agents, today announced that it has developed QuikClot Combat Gauze LE, a new version of its QuikClot Combat Gauze dressing specially designed and packaged for use by law enforcement and first responders.

From Medica Corporation 18 Jan 2011

DKMA issues GMP certificate to Cambrex Zenara Indian manufacturing facility

Cambrex Corporation announced today that the Danish Medicines Agency (DKMA) has issued a Certificate of Good Manufacturing Practice (GMP) compliance for its manufacturing site in Hyderabad, India, following an audit conducted in October 2010. The DKMA Certificate is accepted by all EU Health Authorities and by authorities of several other countries that recognize EU Certification.

18 Jan 2011

Transcept announces Intermezzo NDA resubmission for treatment of middle of the night awakenings

Transcept Pharmaceuticals, Inc. today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of Intermezzo® for use as needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep.

18 Jan 2011

Cadence launches OFIRMEV pain medication in the U.S.

Cadence Pharmaceuticals, Inc. today announced the launch of OFIRMEV™ (acetaminophen) injection, the first and only intravenous (IV) formulation of acetaminophen to be approved in the United States. The U.S. Food and Drug Administration (FDA) approved OFIRMEV in November 2010 for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever.

18 Jan 2011

Mylan receives FDA approval for generic Precose Tablets ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Acarbose Tablets, 25 mg, 50 mg and 100 mg, the generic version of Bayer's Precose® Tablets, a treatment to be used with diet and exercise to improve glycemic control in adults with type 2 diabetes.

18 Jan 2011

Quebec reimburses VIDAZA for treatment of blood cancer

Quebec patients with serious blood cancers (intermediate-2 and high-risk myelodysplastic syndrome and acute myeloid leukemia) now have publicly funded access to a new innovative therapy, VIDAZA® (azacitidine). Following a priority review and subsequent positive recommendation from the Conseil du medicament, patients now have the potential to significantly extend survival.

18 Jan 2011

Seordus recieves Japanese patent for SER100

The Norwegian cardiovascular biopharmaceutical company Seordus AS today announced that the Japanese Patent Office has granted a patent for Japan covering Serodus' proprietary product SER100, an ORL-1 receptor agonist, which Serodus intends to develop for patients with isolated systolic hypertension.

18 Jan 2011

PecFent accepted in Scotland for treatment of breakthrough cancer pain

Archimedes Pharma Ltd., a leading international specialty pharma company, today announced the decision by the Scottish Medicines Consortium to accept PecFent for use within NHS Scotland. PecFent is indicated for the treatment of breakthrough pain in adults who are already receiving maintenance opioid therapy for chronic cancer pain.

18 Jan 2011

OMJPI, Sanford-Burnham enter agreement to discover compounds for Alzheimer's disease, psychiatric disorders

Sanford-Burnham Medical Research Institute has entered into a collaboration with Ortho-McNeil-Janssen Pharmaceuticals, Inc., to discover compounds for Alzheimer's disease and major psychiatric disorders.

18 Jan 2011

T3SS-dependent bacteria may be a suitable point of attack for future antibiotics: Study

So-called type-3 secretion systems of pathogenic bacteria may be a suitable point of attack for future antibiotics. This is shown by Professor Maria Fällman and her associates at Umeå University in Sweden in the Proceeding of the National Academy of Sciences, PNAS, in the US.

18 Jan 2011

McNeil Consumer Healthcare initiates voluntary recall

In consultation with the U.S. Food and Drug Administration, McNeil Consumer Healthcare, Division of McNEIL-PPC, Inc. is voluntarily recalling, at the wholesale level, certain lots of TYLENOL® 8 Hour, TYLENOL® Arthritis Pain, and TYLENOL® upper respiratory products, and certain lots of BENADRYL®, SUDAFED PE®, and SINUTAB® products distributed in the United States, the Caribbean, and Brazil.

18 Jan 2011

Antibiotics with blood pressure medications may cause hypotension

Mixing commonly used antibiotics with common blood pressure medications may cause hypotension and induce shock in older patients, requiring hospitalization, according to a study published in CMAJ.

18 Jan 2011

Study reports warfarin users may face risk of death after traumatic injuries

Warfarin use may be associated with a significant increase in the risk of death after traumatic injuries, according to a report posted online today that will appear in the May print issue of Archives of Surgery, one of the JAMA/Archives journals.

18 Jan 2011

Health Canada approves Eli Lilly's BYETTA for treatment of adults with type 2 diabetes

Eli Lilly Canada is pleased to announce the Health Canada approval of BYETTATM for the treatment of adults with type 2 diabetes.

18 Jan 2011

Pharmacists can help patients to manage their medication and stop smoking

Consulting a pharmacist, or other healthcare professional, when quitting smoking boosts a patient's chance of long-term success from three per cent to 30 per cent.

17 Jan 2011

Capsules with essential oils reduce symptoms of premenstrual syndrome: Study

A pill containing a mix of essential oils has been shown to significantly reduce the symptoms of premenstrual syndrome. Researchers writing in BioMed Central's open access journal Reproductive Health tested the tablets by carrying out a randomised, controlled trial in 120 women.

16 Jan 2011

Study: Health advocacy groups don't always disclose drug company funding

The researchers noted that since these lobbying organizations often urge greater access to new drugs and treatments, these contributions should be made public.

14 Jan 2011